arrow
E

Enriqueta Felip

Vall dHebron Barcelona Hospital Campus
H指数:129
被引数:11.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

可解释AI决策支持工具的临床可用性及非小细胞肺癌中多模态模型的评估

2026-09-130
OAAI
Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment

非小细胞肺癌体细胞拷贝数改变谱及其与一线治疗临床疗效的相关性

2026-04-010
OAAI
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors

基因组可操作性及匹配的靶向疗法在为期十年的机构实体瘤精准医学项目中的应用

2025-11-060
OAAI
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study

一线Sacituzumab Govitecan联合Pembrolizumab治疗转移性NSCLC:EVOKE-02研究PD-L1 TPS <50%和≥50%队列

2025-10-300
PRE
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer

一项时间与动作研究:比较皮下注射帕博利珠单抗与静脉注射帕博利珠单抗联合化疗治疗转移性非小细胞肺癌

2025-10-210
OA
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I NSCLC

TROPION-Lung12:一项关于辅助达波替尼德鲁克坦和瑞尔维斯托米格在ctDNA阳性或高风险病理学Ⅰ期NSCLC中的III期研究

2025-09-190
PRE
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

增强型与标准皮肤管理联合阿曼曲妥珠单抗-拉泽替尼在EGFR突变型晚期NSCLC中的应用比较:COCOON全球随机对照试验

2025-09-090
OAAI
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

携带EGFR突变型晚期非小细胞肺癌患者使用amivantamab-lazertinib的总体生存率

2025-09-019
PRE
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

索托拉西布与多西他赛在经治KRAS G12C突变型晚期非小细胞肺癌中的颅内活性比较:一项全球性、III期、随机对照试验

2025-07-290
OAAI
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Datopotamab Deruxtecan在EGFR突变非小细胞肺癌患者中的合并分析

2025-06-120
OAAI
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report

更新了来自II期PHAROS研究的encorafenib联合binimetinib在BRAF V600E突变型转移性NSCLC患者中的疗效和安全性——简报

2025-06-040
OAAI
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer

EVOKE-01研究:沙库巴曲韦他尼 vs 多西他赛在非小细胞肺癌患者中的疗效对比的简明摘要

2025-05-150
OA
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
2025-03-010
OAAI